## Summary

This paper evaluates small language models (SLMs ≤3B params) and small vision-language models against larger medical-domain models on two clinical NLP tasks: patient-question summarization (MeQSum) and radiology report generation (MIMIC-CXR). It introduces a "Collapse Analysis" measuring task adherence, hallucination rate, concept recall, and prompt robustness across model families. Its strongest finding is a "safety collapse" threshold at ~1B parameters, where hallucination rates spike sharply (from ~2–3% to 18–75%). The paper also contrasts text-only summarization (where small LMs with LoRA fine-tuning become viable) with vision-language report generation (where small VLMs still lag behind large ones).

## Strengths

1. **The within-family scaling analysis (Table 3) identifies a practically important safety threshold.** Tracking hallucination rate, task adherence, and concept recall across SmolLM2 (135M→1.7B) and Gemma-3 (270M→4B) reveals a non-graceful degradation at sub-billion scales. Hallucination rates jumping from ~2–3% at 1.7B to 67.8% (SmolLM2-135M) and 75% (Gemma-3-270M) is a concrete, practically useful finding that does not depend on any comparison to large models. This is the paper's strongest standalone contribution.

2. **The two-modality comparison (text-only vs. vision-language) is informative.** Finding different scaling behaviors — small LMs can be viable with fine-tuning while small VLMs cannot — is more useful than a single-task evaluation. Table 4 provides clear evidence that visual reasoning demands greater model capacity.

3. **The paper tackles a genuinely important practical question.** Whether small, locally-deployable models can substitute for large API-dependent medical LLMs has direct significance for privacy, cost, accessibility, and on-premise deployment in healthcare. This motivation is clearly articulated.

## Weaknesses

### Fatal
None.

### Major

1. **The central comparative claim (small LMs beating large LMs) rests on a confounded comparison.** The paper's headline claim — e.g., "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (line 247) — compares small LMs evaluated *after LoRA fine-tuning* against large LMs evaluated *only with in-context learning (ICL), without any fine-tuning*. Figure 3's data table makes this explicit: the large LMs (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) have dashes in the LoRA column — they were never fine-tuned. This conflates model size *and* adaptation method. The result "fine-tuned small LM beats ICL-only large LM" is practically useful (fine-tuning small models is cheaper), but it does **not** establish that small models are competitive under the same adaptation regime. The paper's abstract ("multiple small models not only reach but occasionally exceed the performance of much larger medical LLMs") and Discussion (line 247) present this as a general finding without acknowledging the confound. The within-family scaling analysis is unaffected, but the headline comparative claim is oversold.

2. **The Collapse Analysis metrics (listed as a primary contribution) are never operationalized.** Table 3 reports Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and a composite "Readiness Score" — yet the paper provides *no description* of how any of these were computed. Were they measured by human evaluation, automated metrics, or LLM-as-judge? What constitutes "Task Adherence"? How was "Hallucination Rate" calculated? What is "Readiness Score"? It appears only in the table header and is never defined. This is listed as Contribution #2 in the Introduction (lines 24–26) but remains a black box, making Table 3 uninterpretable and the entire framework irreproducible.

### Minor

3. **No statistical quantification of results.** All reported scores in Tables 2, 3, and 4 are point estimates on a held-out set of 250 test samples. No confidence intervals, standard deviations, error bars, or significance tests are provided. Given that many metric differences are small (e.g., BERTScore 0.9007 vs. 0.8938 in Table 2; MEDCON 0.295 vs. 0.271) and 250 samples is modest, the reader cannot assess whether reported differences are meaningful or due to noise.

4. **Ambiguous VLM fine-tuning protocol for the large VLMs.** The paper states "After fine-tuning, we compare small VLMs against two large medical VLMs" (line 219) but does not clarify whether Med-Flamingo (9B) and LLaVA-Med v1.5 (7B) were also fine-tuned on the same 10K MIMIC-CXR samples or evaluated in their domain-adapted state without task-specific fine-tuning. If the large VLMs were not fine-tuned on the same data, the comparison has a similar confound as Issue #1 (though less severe, since these models are already medically adapted). An unresolved "Table ??" cross-reference (line 219) further suggests this section was not finalized.

5. **SmolLM3-3B inconsistency.** Table 3 includes a "SmolLM3-3B" entry, but the paper's text only discusses the SmolLM2 family (line 114: "the SmolLM2 and Gemma-3 families"). The SmolLM2 family does not include a 3B variant. This needs clarification or correction.

6. **Key training details absent.** LoRA rank, alpha, learning rate, batch size, number of epochs, which layers LoRA was applied to, and the MeQSum training/test split sizes are never reported, compromising reproducibility.

7. **Anecdotal evidence replacing systematic measurement.** The paper reports that SmolLM2 (1.7B) "began hallucinating—generating more than five distinct questions from a single patient query after fine-tuning" (line 191) as evidence of instability. This is a qualitative anecdote without systematic measurement — inconsistent with the paper's otherwise quantitative approach.

### Trivial

8. **Name inconsistencies across the paper.** "SmollM2" / "SmolLM2" / "SmollLM2" are used interchangeably (e.g., line 15 vs. line 98 vs. line 229), and "Bio Mitral" appears in Figure 1's caption while "BioMistral" is used elsewhere.

## Nice-to-Haves

- **Restructure the paper around the within-family scaling analysis**, which is the strongest and least confounded finding. The "small LMs beat large LMs" framing could be substantially qualified or moved to a secondary finding.
- **Add confidence intervals or error bars** to at least the main comparisons (Tables 2 and 4) to ground claims of superiority.
- **Clarify the VLM comparison protocol** by stating explicitly whether large VLMs were also fine-tuned on MIMIC-CXR.
- **Specify LoRA hyperparameters** (rank, alpha, learning rate, epochs, target modules) to enable reproducibility.

## Removed Points

These points raised by the reviewer are removed (with brief justification):

- *"SmolLM3-3B mentioned before it appears"* — The reviewer's claim about line 114 is inaccurate; line 114 mentions SmolLM2, not SmolLM3. The SmolLM3 inconsistency is already addressed in Minor Weakness #5.
- *"LoRA hyperparameters are completely absent" was categorized as a nitpick about reproducibility by the Hard Rules* — Retained as Minor #6 since LoRA hyperparameters are substantive experimental details, not trivial.
- *Several section-by-section formatting notes* — These are either covered by higher-level weaknesses or are parser artifacts (e.g., "Rest of paper removed" note).
- *"Large LMs have dashes — misleading figure title"* — Already subsumed under Major #1.
- *"Averaging results mitigates prompt sensitivity — no per-prompt variance"* — This is a minor point subsumed by the general lack of statistical reporting (Minor #3).
- *"MeQSum dataset split not described"* — Subsumed under Minor #6 (missing training details).

## Novel Insights

The most penetrating observation from the input review is that the paper's strongest contribution (the safety collapse threshold within model families) and its most attention-grabbing claim (small LMs beating large ones) are essentially independent results resting on different evidence. The safety collapse finding is well-supported by Table 3's within-family data and does not depend on any comparison to large models, while the comparative claim requires a confounded experimental design. This suggests the paper could be substantially strengthened by centering the within-family analysis and presenting the small-vs-large comparison as a secondary, qualified finding.

## Suggestions

1. Either (a) provide LoRA fine-tuning results for the large medical LMs to enable a fair comparison, or (b) substantially qualify the "small LMs exceed large LMs" claim — e.g., "small LMs + LoRA can match large LMs + ICL" — and restructure the paper to foreground the within-family scaling analysis.
2. Fully specify how each Collapse Analysis metric (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, Readiness Score) was computed. Even a brief paragraph defining each would transform Table 3 from a black box into a reproducible methodological contribution.
3. Add statistical uncertainty measures (confidence intervals via bootstrapping, or error bars) for the main comparisons.
4. Resolve the "Table ??" cross-reference and the SmolLM3/SmolLM2 inconsistency.

## Score and Decision

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>